Singapore Institute of Advanced Medicine (SGX:9G2) trimmed its loss after tax for the fiscal first half ended Dec. 31, 2024 to SG$12.6 million from SG$21.2 million a year earlier, according to a Monday filing with the Singapore Exchange.
Loss per share from continuing operations decreased to SG$0.0135 from SG$0.0311 in the comparable period.
Revenue, however, declined 6% year over year to SG$8.0 million from SG$8.5 million.